1-20 of 20
David M. Hyman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

José “Pepe” Baselga, MD, PhD: In Memoriam (1959–2021)

Josep Tabernero, David M. Hyman, Jean-Charles Soria
Journal: Cancer Discovery
Cancer Discov (2021) 11 (7): 1614–1616.
https://doi.org/10.1158/2159-8290.CD-21-0458
Published: 01 July 2021
View article titled, José “Pepe” Baselga, MD, PhD: In Memoriam (1959–2021)
Open the PDF for José “Pepe” Baselga, MD, PhD: In Memoriam (1959–2021) in another window
Journal Articles

TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors

Emiliano Cocco, Ji Eun Lee, Srinivasaraghavan Kannan, Alison M. Schram, Helen H. Won, Sophie Shifman, Amanda Kulick, Laura Baldino, Eneda Toska, Amaia Arruabarrena-Aristorena, Srushti Kittane, Fan Wu, Yanyan Cai, Sabrina Arena, Benedetta Mussolin, Ram Kannan, Neil Vasan, Alexander N. Gorelick, Michael F. Berger, Ofra Novoplansky, Sankar Jagadeeshan, Yi Liao, Uwe Rix, Sandra Misale, Barry S. Taylor, Alberto Bardelli, Jaclyn F. Hechtman, David M. Hyman, Moshe Elkabets, Elisa de Stanchina, Chandra S. Verma, Andrea Ventura, Alexander Drilon, Maurizio Scaltriti
Journal: Cancer Discovery
Cancer Discov (2021) 11 (1): 126–141.
https://doi.org/10.1158/2159-8290.CD-20-0571
Published: 06 January 2021
View article titled, TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors
Open the PDF for TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors in another window
Includes: Supplementary data
Journal Articles

HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers

Bob T. Li, Flavia Michelini, Sandra Misale, Emiliano Cocco, Laura Baldino, Yanyan Cai, Sophie Shifman, Hai-Yan Tu, Mackenzie L. Myers, Chongrui Xu, Marissa Mattar, Inna Khodos, Megan Little, Besnik Qeriqi, Gregory Weitsman, Clare J. Wilhem, Alshad S. Lalani, Irmina Diala, Rachel A. Freedman, Nancy U. Lin, David B. Solit, Michael F. Berger, Paul R. Barber, Tony Ng, Michael Offin, James M. Isbell, David R. Jones, Helena A. Yu, Sheeno Thyparambil, Wei-Li Liao, Anuja Bhalkikar, Fabiola Cecchi, David M. Hyman, Jason S. Lewis, Darren J. Buonocore, Alan L. Ho, Vicky Makker, Jorge S. Reis-Filho, Pedram Razavi, Maria E. Arcila, Mark G. Kris, John T. Poirier, Ronglai Shen, Junji Tsurutani, Gary A. Ulaner, Elisa de Stanchina, Neal Rosen, Charles M. Rudin, Maurizio Scaltriti
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2020) 10 (5): 674–687.
https://doi.org/10.1158/2159-8290.CD-20-0215
Published: 01 May 2020
View article titled, HER2-Mediated Internalization of Cytotoxic Agents in <em>ERBB2</em> Amplified or Mutant Lung Cancers
Open the PDF for HER2-Mediated Internalization of Cytotoxic Agents in <em>ERBB2</em> Amplified or Mutant Lung Cancers in another window
Includes: Supplementary data
Journal Articles

Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers

Vivek Subbiah, Igor Puzanov, Jean-Yves Blay, Ian Chau, A. Craig Lockhart, Noopur S. Raje, Juergen Wolf, José Baselga, Funda Meric-Bernstam, Jason Roszik, Eli L. Diamond, Gregory J. Riely, Eric J. Sherman, Todd Riehl, Bethany Pitcher, David M. Hyman
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2020) 10 (5): 657–663.
https://doi.org/10.1158/2159-8290.CD-19-1265
Published: 01 May 2020
View article titled, Pan-Cancer Efficacy of Vemurafenib in <em>BRAF</em><sup>V600</sup>-Mutant Non-Melanoma Cancers
Open the PDF for Pan-Cancer Efficacy of Vemurafenib in <em>BRAF</em><sup>V600</sup>-Mutant Non-Melanoma Cancers in another window
Includes: Supplementary data
Journal Articles

Characteristics and Outcome of AKT1E17K-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry

Lillian M. Smyth, Qin Zhou, Bastien Nguyen, Celeste Yu, Eva M. Lepisto, Monica Arnedos, Michael J. Hasset, Michele L. Lenoue-Newton, Natalie Blauvelt, Semih Dogan, Christine M. Micheel, Chetna Wathoo, Hugo Horlings, Jan Hudecek, Benjamin E. Gross, Ritika Kundra, Shawn M. Sweeney, JianJiong Gao, Nikolaus Schultz, Andrew Zarski, Stuart M. Gardos, Jocelyn Lee, Seth Sheffler-Collins, Ben H. Park, Charles L. Sawyers, Fabrice André, Mia Levy, Funda Meric-Bernstam, Philippe L. Bedard, Alexia Iasonos, Deborah Schrag, David M. Hyman
Journal: Cancer Discovery
Cancer Discov (2020) 10 (4): 526–535.
https://doi.org/10.1158/2159-8290.CD-19-1209
Published: 01 April 2020
View article titled, Characteristics and Outcome of <em>AKT1</em><sup>E17K</sup>-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry
Open the PDF for Characteristics and Outcome of <em>AKT1</em><sup>E17K</sup>-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry in another window
Includes: Supplementary data
Journal Articles

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

Lillian M. Smyth, Sarina A. Piha-Paul, Helen H. Won, Alison M. Schram, Cristina Saura, Sherene Loi, Janice Lu, Geoffrey I. Shapiro, Dejan Juric, Ingrid A. Mayer, Carlos L. Arteaga, Macarena I. de la Fuente, Adam M. Brufksy, Iben Spanggaard, Morten Mau-Sørensen, Monica Arnedos, Victor Moreno, Valentina Boni, Joohyuk Sohn, Lee S. Schwartzberg, Xavier Gonzàlez-Farré, Andrés Cervantes, François-Clement Bidard, Alexander N. Gorelick, Richard B. Lanman, Rebecca J. Nagy, Gary A. Ulaner, Sarat Chandarlapaty, Komal Jhaveri, Elena I. Gavrila, Catherine Zimel, S. Duygu Selcuklu, Myra Melcer, Aliaksandra Samoila, Yanyan Cai, Maurizio Scaltriti, Grace Mann, Feng Xu, Lisa D. Eli, Melanie Dujka, Alshad S. Lalani, Richard Bryce, José Baselga, Barry S. Taylor, David B. Solit, Funda Meric-Bernstam, David M. Hyman
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2020) 10 (2): 198–213.
https://doi.org/10.1158/2159-8290.CD-19-0966
Published: 05 February 2020
View article titled, Efficacy and Determinants of Response to HER Kinase Inhibition in <em>HER2</em>-Mutant Metastatic Breast Cancer
Open the PDF for Efficacy and Determinants of Response to HER Kinase Inhibition in <em>HER2</em>-Mutant Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel AKT1 Fusion–Driven Cancer

Emily K. Slotkin, Daniel Diolaiti, Neerav N. Shukla, Filemon S. Dela Cruz, Jennifer J. Clark, Gunes Gundem, Venkata D. Yellapantula, Max F. Levine, Daoqi You, Peilin Ma, Sagarika Pachhal, Glorymar Ibanez Sanchez, Ryma Benayed, Achim A. Jungbluth, Lillian M. Smyth, Audrey Mauguen, Irena Gushterova, Hongxu Ding, Lee Spraggon, Robert Darnell, Andrea Califano, Marc Ladanyi, Elli Papaemmanuil, Andrew L. Kung, David M. Hyman, Stephen S. Roberts
Journal: Cancer Discovery
Cancer Discov (2019) 9 (5): 605–616.
https://doi.org/10.1158/2159-8290.CD-18-0953
Published: 01 May 2019
View article titled, Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel <em>AKT1</em> Fusion–Driven Cancer
Open the PDF for Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel <em>AKT1</em> Fusion–Driven Cancer in another window
Includes: Supplementary data
Journal Articles

Correction: An Acquired HER2T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer

Ariella B. Hanker, Monica Red Brewer, Jonathan H. Sheehan, James P. Koch, Gregory R. Sliwoski, Rebecca Nagy, Richard Lanman, Michael F. Berger, David M. Hyman, David B. Solit, Jie He, Vincent Miller, Richard E. Cutler, Jr, Alshad S. Lalani, Darren Cross, Christine M. Lovly, Jens Meiler, Carlos L. Arteaga
Journal: Cancer Discovery
Cancer Discov (2019) 9 (2): 303.
https://doi.org/10.1158/2159-8290.CD-18-1515
Published: 08 February 2019
View article titled, Correction: An Acquired <em>HER2</em><sup>T798I</sup> Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer
Open the PDF for Correction: An Acquired <em>HER2</em><sup>T798I</sup> Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer in another window
Journal Articles

Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition

James J. Harding, Maeve A. Lowery, Alan H. Shih, Juan M. Schvartzman, Shengqi Hou, Christopher Famulare, Minal Patel, Mikhail Roshal, Richard K. Do, Ahmet Zehir, Daoqi You, S. Duygu Selcuklu, Agnes Viale, Martin S. Tallman, David M. Hyman, Ed Reznik, Lydia W.S. Finley, Elli Papaemmanuil, Alessandra Tosolini, Mark G. Frattini, Kyle J. MacBeth, Guowen Liu, Bin Fan, Sung Choe, Bin Wu, Yelena Y. Janjigian, Ingo K. Mellinghoff, Luis A. Diaz, Ross L. Levine, Ghassan K. Abou-Alfa, Eytan M. Stein, Andrew M. Intlekofer
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2018) 8 (12): 1540–1547.
https://doi.org/10.1158/2159-8290.CD-18-0877
Published: 03 December 2018
View article titled, Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition
Open the PDF for Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition in another window
Includes: Supplementary data
Journal Articles

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations

Alexander Drilon, Sai-Hong Ignatius Ou, Byoung Chul Cho, Dong-Wan Kim, Jeeyun Lee, Jessica J. Lin, Viola W. Zhu, Myung-Ju Ahn, D. Ross Camidge, Judy Nguyen, Dayong Zhai, Wei Deng, Zhongdong Huang, Evan Rogers, Juliet Liu, Jeff Whitten, John K. Lim, Shanna Stopatschinskaja, David M. Hyman, Robert C. Doebele, J. Jean Cui, Alice T. Shaw
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2018) 8 (10): 1227–1236.
https://doi.org/10.1158/2159-8290.CD-18-0484
Published: 02 October 2018
View article titled, Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations
Open the PDF for Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations in another window
Includes: Supplementary data
Journal Articles

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

Ryan J. Sullivan, Jeffrey R. Infante, Filip Janku, Deborah Jean Lee Wong, Jeffrey A. Sosman, Vicki Keedy, Manish R. Patel, Geoffrey I. Shapiro, James W. Mier, Anthony W. Tolcher, Andrea Wang-Gillam, Mario Sznol, Keith Flaherty, Elizabeth Buchbinder, Richard D. Carvajal, Anna M. Varghese, Mario E. Lacouture, Antoni Ribas, Sapna P. Patel, Gary A. DeCrescenzo, Caroline M. Emery, Anna L. Groover, Saurabh Saha, Mary Varterasian, Dean J. Welsch, David M. Hyman, Bob T. Li
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2018) 8 (2): 184–195.
https://doi.org/10.1158/2159-8290.CD-17-1119
Published: 04 February 2018
View article titled, First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
Open the PDF for First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study in another window
Includes: Supplementary data
Journal Articles

Accelerating Discovery of Functional Mutant Alleles in Cancer

Matthew T. Chang, Tripti Shrestha Bhattarai, Alison M. Schram, Craig M. Bielski, Mark T.A. Donoghue, Philip Jonsson, Debyani Chakravarty, Sarah Phillips, Cyriac Kandoth, Alexander Penson, Alexander Gorelick, Tambudzai Shamu, Swati Patel, Christopher Harris, JianJiong Gao, Selcuk Onur Sumer, Ritika Kundra, Pedram Razavi, Bob T. Li, Dalicia N. Reales, Nicholas D. Socci, Gowtham Jayakumaran, Ahmet Zehir, Ryma Benayed, Maria E. Arcila, Sarat Chandarlapaty, Marc Ladanyi, Nikolaus Schultz, José Baselga, Michael F. Berger, Neal Rosen, David B. Solit, David M. Hyman, Barry S. Taylor
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2018) 8 (2): 174–183.
https://doi.org/10.1158/2159-8290.CD-17-0321
Published: 04 February 2018
View article titled, Accelerating Discovery of Functional Mutant Alleles in Cancer
Open the PDF for Accelerating Discovery of Functional Mutant Alleles in Cancer in another window
Includes: Supplementary data
Journal Articles

Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer

Yelena Y. Janjigian, Francisco Sanchez-Vega, Philip Jonsson, Walid K. Chatila, Jaclyn F. Hechtman, Geoffrey Y. Ku, Jamie C. Riches, Yaelle Tuvy, Ritika Kundra, Nancy Bouvier, Efsevia Vakiani, Jianjiong Gao, Zachary J. Heins, Benjamin E. Gross, David P. Kelsen, Liying Zhang, Vivian E. Strong, Mark Schattner, Hans Gerdes, Daniel G. Coit, Manjit Bains, Zsofia K. Stadler, Valerie W. Rusch, David R. Jones, Daniela Molena, Jinru Shia, Mark E. Robson, Marinela Capanu, Sumit Middha, Ahmet Zehir, David M. Hyman, Maurizio Scaltriti, Marc Ladanyi, Neal Rosen, David H. Ilson, Michael F. Berger, Laura Tang, Barry S. Taylor, David B. Solit, Nikolaus Schultz
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2018) 8 (1): 49–58.
https://doi.org/10.1158/2159-8290.CD-17-0787
Published: 07 January 2018
View article titled, Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer
Open the PDF for Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer in another window
Includes: Supplementary data
Journal Articles

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors

Alexander Drilon, Ramamoorthy Nagasubramanian, James F. Blake, Nora Ku, Brian B. Tuch, Kevin Ebata, Steve Smith, Veronique Lauriault, Gabrielle R. Kolakowski, Barbara J. Brandhuber, Paul D. Larsen, Karyn S. Bouhana, Shannon L. Winski, Robyn Hamor, Wen-I Wu, Andrew Parker, Tony H. Morales, Francis X. Sullivan, Walter E. DeWolf, Lance A. Wollenberg, Paul R. Gordon, Dorothea N. Douglas-Lindsay, Maurizio Scaltriti, Ryma Benayed, Sandeep Raj, Bethany Hanusch, Alison M. Schram, Philip Jonsson, Michael F. Berger, Jaclyn F. Hechtman, Barry S. Taylor, Steve Andrews, S. Michael Rothenberg, David M. Hyman
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2017) 7 (9): 963–972.
https://doi.org/10.1158/2159-8290.CD-17-0507
Published: 31 August 2017
View article titled, A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors
Open the PDF for A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors in another window
Includes: Supplementary data
Journal Articles

AACR Project GENIE: Powering Precision Medicine through an International Consortium

The AACR Project GENIE Consortium, The AACR Project GENIE Consortium, Fabrice André, Monica Arnedos, Alexander S. Baras, José Baselga, Philippe L. Bedard, Michael F. Berger, Mariska Bierkens, Fabien Calvo, Ethan Cerami, Debyani Chakravarty, Kristen K. Dang, Nancy E. Davidson, Catherine Del Vecchio Fitz, Semih Dogan, Raymond N. DuBois, Matthew D. Ducar, P. Andrew Futreal, Jianjiong Gao, Francisco Garcia, Stu Gardos, Christopher D. Gocke, Benjamin E. Gross, Justin Guinney, Zachary J. Heins, Stephanie Hintzen, Hugo Horlings, Jan Hudeček, David M. Hyman, Suzanne Kamel-Reid, Cyriac Kandoth, Walter Kinyua, Priti Kumari, Ritika Kundra, Marc Ladanyi, Céline Lefebvre, Michele L. LeNoue-Newton, Eva M. Lepisto, Mia A. Levy, Neal I. Lindeman, James Lindsay, David Liu, Zhibin Lu, Laura E. MacConaill, Ian Maurer, David S. Maxwell, Gerrit A. Meijer, Funda Meric-Bernstam, Christine M. Micheel, Clinton Miller, Gordon Mills, Nathanael D. Moore, Petra M. Nederlof, Larsson Omberg, John A. Orechia, Ben Ho Park, Trevor J. Pugh, Brendan Reardon, Barrett J. Rollins, Mark J. Routbort, Charles L. Sawyers, Deborah Schrag, Nikolaus Schultz, Kenna R Mills Shaw, Priyanka Shivdasani, Lillian L. Siu, David B. Solit, Gabe S. Sonke, Jean Charles Soria, Parin Sripakdeevong, Natalie H. Stickle, Thomas P. Stricker, Shawn M. Sweeney, Barry S. Taylor, Jelle J. ten Hoeve, Stacy B. Thomas, Eliezer M. Van Allen, Laura J. Van 'T Veer, Tony van de Velde, Harm van Tinteren, Victor E. Velculescu, Carl Virtanen, Emile E. Voest, Lucy L. Wang, Chetna Wathoo, Stuart Watt, Celeste Yu, Thomas V. Yu, Emily Yu, Ahmet Zehir, Hongxin Zhang
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2017) 7 (8): 818–831.
https://doi.org/10.1158/2159-8290.CD-17-0151
Published: 01 August 2017
View article titled, AACR Project GENIE: Powering Precision Medicine through an International Consortium
Open the PDF for AACR Project GENIE: Powering Precision Medicine through an International Consortium in another window
Includes: Supplementary data
Journal Articles

Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies

Emmet J. Jordan, Hyunjae R. Kim, Maria E. Arcila, David Barron, Debyani Chakravarty, JianJiong Gao, Matthew T. Chang, Andy Ni, Ritika Kundra, Philip Jonsson, Gowtham Jayakumaran, Sizhi Paul Gao, Hannah C. Johnsen, Aphrothiti J. Hanrahan, Ahmet Zehir, Natasha Rekhtman, Michelle S. Ginsberg, Bob T. Li, Helena A. Yu, Paul K. Paik, Alexander Drilon, Matthew D. Hellmann, Dalicia N. Reales, Ryma Benayed, Valerie W. Rusch, Mark G. Kris, Jamie E. Chaft, José Baselga, Barry S. Taylor, Nikolaus Schultz, Charles M. Rudin, David M. Hyman, Michael F. Berger, David B. Solit, Marc Ladanyi, Gregory J. Riely
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2017) 7 (6): 596–609.
https://doi.org/10.1158/2159-8290.CD-16-1337
Published: 01 June 2017
View article titled, Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
Open the PDF for Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies in another window
Includes: Supplementary data
Journal Articles

An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer

Ariella B. Hanker, Monica Red Brewer, Jonathan H. Sheehan, James P. Koch, Gregory R. Sliwoski, Rebecca Nagy, Richard Lanman, Michael F. Berger, David M. Hyman, David B. Solit, Jie He, Vincent Miller, Richard E. Cutler, Jr, Alshad S. Lalani, Darren Cross, Christine M. Lovly, Jens Meiler, Carlos L. Arteaga
Journal: Cancer Discovery
Cancer Discov (2017) 7 (6): 575–585.
https://doi.org/10.1158/2159-8290.CD-16-1431
Published: 01 June 2017
View article titled, An Acquired <em>HER2</em> <sup>T798I</sup> Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer
Open the PDF for An Acquired <em>HER2</em> <sup>T798I</sup> Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Quantifying the Benefits of Genome-Driven Oncology

Alison M. Schram, David M. Hyman
Journal: Cancer Discovery
Cancer Discov (2017) 7 (6): 552–554.
https://doi.org/10.1158/2159-8290.CD-17-0380
Published: 01 June 2017
View article titled, Quantifying the Benefits of Genome-Driven Oncology
Open the PDF for Quantifying the Benefits of Genome-Driven Oncology in another window
Journal Articles

Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms

Eli L. Diamond, Benjamin H. Durham, Julien Haroche, Zhan Yao, Jing Ma, Sameer A. Parikh, Zhaoming Wang, John Choi, Eunhee Kim, Fleur Cohen-Aubart, Stanley Chun-Wei Lee, Yijun Gao, Jean-Baptiste Micol, Patrick Campbell, Michael P. Walsh, Brooke Sylvester, Igor Dolgalev, Olga Aminova, Adriana Heguy, Paul Zappile, Joy Nakitandwe, Chezi Ganzel, James D. Dalton, David W. Ellison, Juvianee Estrada-Veras, Mario Lacouture, William A. Gahl, Philip J. Stephens, Vincent A. Miller, Jeffrey S. Ross, Siraj M. Ali, Samuel R. Briggs, Omotayo Fasan, Jared Block, Sebastien Héritier, Jean Donadieu, David B. Solit, David M. Hyman, José Baselga, Filip Janku, Barry S. Taylor, Christopher Y. Park, Zahir Amoura, Ahmet Dogan, Jean-Francois Emile, Neal Rosen, Tanja A. Gruber, Omar Abdel-Wahab
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2016) 6 (2): 154–165.
https://doi.org/10.1158/2159-8290.CD-15-0913
Published: 04 February 2016
View article titled, Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms
Open the PDF for Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms in another window
Includes: Supplementary data
Journal Articles

Prospective Blinded Study of BRAFV600E Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders

David M. Hyman, Eli L. Diamond, Cecile Rose T. Vibat, Latifa Hassaine, Jason C. Poole, Minal Patel, Veronica R. Holley, Goran Cabrilo, Timothy T. Lu, Maria E. Arcila, Young Rock Chung, Raajit Rampal, Mario E. Lacouture, Neal Rosen, Funda Meric-Bernstam, José Baselga, Razelle Kurzrock, Mark G. Erlander, Filip Janku, Omar Abdel-Wahab
Journal: Cancer Discovery
Cancer Discov (2015) 5 (1): 64–71.
https://doi.org/10.1158/2159-8290.CD-14-0742
Published: 11 January 2015
View article titled, Prospective Blinded Study of <em>BRAF</em><sup>V600E</sup> Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders
Open the PDF for Prospective Blinded Study of <em>BRAF</em><sup>V600E</sup> Mutation Detection in Cell-Free DNA of Patients with Systemic Histiocytic Disorders in another window
Includes: Supplementary data